Detalhe da pesquisa
1.
Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 28(3): 239-245, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36427017
2.
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Oncologist
; 28(12): 1072-1078, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285524
3.
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Oncologist
; 26(11): 956-964, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096667
4.
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 26(10): e1742-e1750, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156726
5.
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 26(5): 397-405, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33634507
6.
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Oncologist
; 26(12): 1017-1025, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34342095
7.
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus.
J Immunother Precis Oncol
; 6(1): 50-55, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36751655
8.
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
Urol Oncol
; 40(6): 271.e9-271.e18, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466038
9.
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Clin Genitourin Cancer
; 20(1): 53-59, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922840
10.
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.
J Immunother Precis Oncol
; 5(3): 52-57, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36034580
11.
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series.
Case Rep Oncol
; 14(1): 190-196, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33776702
12.
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.
Front Oncol
; 11: 701345, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34222024
13.
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326170
14.
Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Cancer Treat Res Commun
; 28: 100393, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34029879
15.
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Front Oncol
; 11: 707050, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307176